Janney Montgomery Scott Downgrades Cerulean Pharma (CERU) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Leerink Partners Downgrades Cerulean Pharma (CERU) to Market Perform
August 18, 2016 7:29 AM EDTLeerink Partners downgraded Cerulean Pharma (NASDAQ: CERU) from Outperform to Market Perform with a price target of $1.50 (from $8.00). The change follows disappointed CRLX-101 trial results.
"We are downgrading CERU to MP following the failure of lead product candidate CRLX-101 (camptothecin nanoparticle-drug conjugate/NDC) in a... More
Cerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed Primary Endpoint
August 17, 2016 4:02 PM EDTCerulean Pharma Inc. (Nasdaq: CERU) announced top-line results from the Companys Phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin® (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC).
The trial was conducted at 43 sites in the US and South Korea, and enrolled 115 patients with RCC who progressed... More
Cerulean Pharma (CERU) halted with news pending
August 17, 2016 4:00 PM EDTCerulean Pharma (NASDAQ: CERU) halted with news pending.
... More
